References:
1. RAK K, R J, S P, SV M. Side effects of BNT162b2 mRNA COVID-19
vaccine: A randomized, cross-sectional study with detailed self-reported
symptoms from healthcare workers. Int J Infect Dis [Internet]. 2021
May 1 [cited 2021 Aug 29];106:376–81. Available from:
https://pubmed.ncbi.nlm.nih.gov/33866000/
2. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M.
Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in
the Czech Republic. J Clin Med [Internet]. 2021 Apr 1 [cited 2021
Aug 29];10(7):1428. Available from: /pmc/articles/PMC8037149/
3. NH S, IH S, AE M, LA M, F L-J, MT A, et al. Thrombosis and
Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med
[Internet]. 2021 Jun 3 [cited 2021 Aug 30];384(22):2124–30.
Available from: https://pubmed.ncbi.nlm.nih.gov/33835768/
4. A G, T T, TE W, K W, PA K, S E. Thrombotic Thrombocytopenia after
ChAdOx1 nCov-19 Vaccination. N Engl J Med [Internet]. 2021 Jun 3
[cited 2021 Aug 30];384(22):2092–101. Available from:
https://pubmed.ncbi.nlm.nih.gov/33835769/
5. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al.
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19
Vaccination. https://doi.org/101056/NEJMoa2105385 [Internet]. 2021
Apr 16 [cited 2021 Aug 30];384(23):2202–11. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa2105385
6. Bae S, Lee YW, Lim SY, Lee J-H, Lim JS, Lee S, et al. Adverse
Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and
BNT162b2 Vaccine for Healthcare Workers in South Korea. J Korean Med Sci
[Internet]. 2021 [cited 2021 Aug 30];36(17):1–9. Available
from: /pmc/articles/PMC8093607/
7. C GC, A C, G CH, P R-J, D F-N, A R-VL, et al. Classification of the
cutaneous manifestations of COVID-19: a rapid prospective nationwide
consensus study in Spain with 375 cases. Br J Dermatol [Internet].
2020 Jul 1 [cited 2021 Aug 30];183(1):71–7. Available from:
https://pubmed.ncbi.nlm.nih.gov/32348545/
8. AV M, G G, C M, V G, P V, V M, et al. The clinical spectrum of
COVID-19-associated cutaneous manifestations: An Italian multicenter
study of 200 adult patients. J Am Acad Dermatol [Internet]. 2021 May
1 [cited 2021 Aug 30];84(5):1356–63. Available from:
https://pubmed.ncbi.nlm.nih.gov/33476725/
9. Aleem A, Nadeem AJ. Coronavirus (COVID-19) Vaccine-Induced Immune
Thrombotic Thrombocytopenia (VITT). StatPearls [Internet]. 2021 Jul
18 [cited 2021 Aug 30]; Available from:
https://www.ncbi.nlm.nih.gov/books/NBK570605/
10. CA N, U B, EM S, P S, I R, EA R, et al. A method for estimating the
probability of adverse drug reactions. Clin Pharmacol Ther
[Internet]. 1981 [cited 2021 Aug 30];30(2):239–45. Available
from: https://pubmed.ncbi.nlm.nih.gov/7249508/
11. The use of the WHO-UMC system for standardised case causality
assessment [Internet]. [cited 2021 Aug 30]. Available from:
https://www.who.int/publications/m/item/WHO-causality-assessment
12. Preventability and severity assessment in reporting adverse drug
reactions - PubMed [Internet]. [cited 2021 Aug 30]. Available
from: https://pubmed.ncbi.nlm.nih.gov/1524068/
13. Adverse drug reactions. A critical review - PubMed [Internet].
[cited 2021 Aug 30]. Available from:
https://pubmed.ncbi.nlm.nih.gov/1242749/
14. D D, SJ P, CR K, A M, AS L-C, VA L, et al. Autoimmune encephalitis
epidemiology and a comparison to infectious encephalitis. Ann Neurol
[Internet]. 2018 Jan 1 [cited 2021 Aug 30];83(1):166–77.
Available from: https://pubmed.ncbi.nlm.nih.gov/29293273/
15. F Z, T G, R K, WR S, A R. Postvaccinal Encephalitis after ChAdOx1
nCov-19. Ann Neurol [Internet]. 2021 Aug 13 [cited 2021 Aug 30];
Available from: https://pubmed.ncbi.nlm.nih.gov/34324214/
16. A V, AR T, KC B, AS L, J S, A B, et al. Case definitions, diagnostic
algorithms, and priorities in encephalitis: consensus statement of the
international encephalitis consortium. Clin Infect Dis [Internet].
2013 Oct 15 [cited 2021 Aug 30];57(8):1114–28. Available from:
https://pubmed.ncbi.nlm.nih.gov/23861361/
17. L B, G A, A M, I P, S R, P C, et al. Hyperacute reversible
encephalopathy related to cytokine storm following COVID-19 vaccine. J
Neuroimmunol [Internet]. 2021 Sep 15 [cited 2021 Aug 30];358.
Available from: https://pubmed.ncbi.nlm.nih.gov/34284342/
18. G T-A, JC M, Y H, CR G, MR S, SK A, et al. Acute encephalitis,
myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Rep
[Internet]. 2021 Jul [cited 2021 Aug 30];14(7):e243173.
Available from: https://pubmed.ncbi.nlm.nih.gov/34312136/
19. Franchini M, Liumbruno GM, Pezzo M. COVID‐19 vaccine‐associated
immune thrombosis and thrombocytopenia (VITT): Diagnostic and
therapeutic recommendations for a new syndrome. Eur J Haematol
[Internet]. 2021 Aug 1 [cited 2021 Aug 30];107(2):173–80.
Available from: /pmc/articles/PMC8239516/
20. Muir K-L, Kallam A, Koepsell SA, Gundabolu K. Thrombotic
Thrombocytopenia after Ad26.COV2.S Vaccination.
https://doi.org/101056/NEJMc2105869 [Internet]. 2021 Apr 14 [cited
2021 Aug 30];384(20):1964–5. Available from:
https://www.nejm.org/doi/full/10.1056/NEJMc2105869
21. Cines DB, Bussel JB. SARS-CoV-2 Vaccine–Induced Immune Thrombotic
Thrombocytopenia. https://doi.org/101056/NEJMe2106315 [Internet].
2021 Apr 16 [cited 2021 Aug 30];384(23):2254–6. Available from:
https://www.nejm.org/doi/full/10.1056/nejme2106315
22. Sangli S, Virani A, Cheronis N, Vannatter B, Minich C, Noronha S, et
al. Thrombosis With Thrombocytopenia After the Messenger RNA–1273
Vaccine. Ann Intern Med [Internet]. 2021 Jun 29 [cited 2021 Aug
30]; Available from: /pmc/articles/PMC8251935/
23. JS A-M, S AR, MS K, AM AH, H F, B AR, et al. A 59-Year-Old Woman
with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days
Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19
Vaccine. Am J Case Rep [Internet]. 2021 [cited 2021 Aug
30];22(1). Available from: https://pubmed.ncbi.nlm.nih.gov/34117206/
24. Leukocytoclastic Vasculitis - PubMed [Internet]. [cited 2021
Aug 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/29489227/
25. C B, F T, P F, GS A, C S, NS B, et al. Vasculitis as an adverse
event following immunization - Systematic literature review. Vaccine
[Internet]. 2016 Dec 12 [cited 2021 Aug 30];34(51):6641–51.
Available from: https://pubmed.ncbi.nlm.nih.gov/26398442/
26. Casas CG, Català A, Hernández GC, Rodríguez-Jiménez P,
Fernández-Nieto D, Lario AR-V, et al. Classification of the cutaneous
manifestations of COVID-19: a rapid prospective nationwide consensus
study in Spain with 375 cases. Br J Dermatol [Internet]. 2020 Jul 1
[cited 2021 Aug 30];183(1):71–7. Available from:
https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.19163
27. DE M, E A, M R, JB L, D M, A T, et al. Cutaneous reactions reported
after Moderna and Pfizer COVID-19 vaccination: A registry-based study of
414 cases. J Am Acad Dermatol [Internet]. 2021 Jul 1 [cited 2021
Aug 30];85(1):46–55. Available from:
https://pubmed.ncbi.nlm.nih.gov/33838206/
28. L G-P, M P-P, D F-L, J M-M, C G-C, JL R-P, et al. Small-vessel
vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2.
J Eur Acad Dermatol Venereol [Internet]. 2021 Aug 4 [cited 2021
Aug 30]; Available from: https://pubmed.ncbi.nlm.nih.gov/34310763/
29. Berry CT, Eliliwi M, Gallagher S, Panaccione S, Klein WM, Healy AL,
et al. Cutaneous small vessel vasculitis following single-dose Janssen
Ad26.COV2.S vaccination. JAAD Case Reports [Internet]. 2021 Sep
[cited 2021 Aug 30];15:11. Available from: /pmc/articles/PMC8302840/